PET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma

References

• Subocz E, Hałka J, Dziuk M. The role of FDG-PET in Hodgkin lymphoma. Contemp Oncol (Pozn). 2017;21(2):104–114.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. JCO. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. JCO. 2017;35(16):1786–1794.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607.
   PubMed Web of Science ®Google Scholar
• Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 Trial by the German Hodgkin Study Group. JCO. 2019;37(31):2835–2845.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;20(17):32134–32137.
   Google Scholar
• Casasnovas R-O, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–215.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Kreissl S, Goergen H, et al. Intensive treatment strategies in advanced-stage Hodgkin’s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018;5(10):e462–e73.
   PubMed Web of Science ®Google Scholar
• Engert A, Goergen H, Markova J, et al. Reduced-intensity chemotherapy in patients with advanced-stage Hodgkin lymphoma: updated results of the open-label, international, randomised phase 3 HD15 trial by the German Hodgkin Study Group. HemaSphere. 2017;1(1):e5.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;23(4999396):iv19–iv29.
   Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma version 1.2017, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2017;15(5):608–638.
   PubMed Web of Science ®Google Scholar
• Novo M, Nowakowski GS, Habermann TM, et al. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? Leuk Lymphoma. 2019;60:1–10.
   PubMedGoogle Scholar
• Bröckelmann PJ, Eichenauer DA, Jakob T, et al. Hodgkin-Lymphom beim erwachsenen Patienten. Dtsch Arztebl Int. 2018;115(31–32):535–540.
   PubMedGoogle Scholar
• Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98(10):2930–2934.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429–433.
   PubMed Web of Science ®Google Scholar
• Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. JCO. 1988;6(6):940–946.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 Trial. JCO. 2018;36(5):454–462.
   PubMed Web of Science ®Google Scholar
• Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
   PubMed Web of Science ®Google Scholar
• Schaefer NG, Taverna C, Strobel K, et al. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG-avid lesions still needed? Radiology. 2007;244(1):257–262.
   PubMed Web of Science ®Google Scholar
• Carella AM, Bellei M, Brice P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica. 2009;94(1):146–148.
   PubMed Web of Science ®Google Scholar
• Arakelyan N, Berthou C, Desablens B, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma—3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation. Cancer. 2008;113(12):3323–3330.
   PubMed Web of Science ®Google Scholar